STOCK TITAN

Assembly Bioscie - ASMB STOCK NEWS

Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.

Company Overview

Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology company dedicated to the discovery and development of novel oral therapeutics designed to address serious viral diseases. With a dual-platform strategy focused on innovative approaches, the company is advancing a new class of oral antiviral therapeutics for hepatitis B virus (HBV) infection as well as pioneering oral live biotherapeutics aimed at restoring the health of dysbiotic microbiomes.

Innovative Therapeutic Platforms

The company’s strategic development is built on two core programs:

  • HBV Therapeutics: Assembly Biosciences is developing investigational small-molecule compounds that target critical phases of the HBV lifecycle. These candidates aim to overcome the limitations of current chronic HBV treatments by targeting multiple steps in viral replication and reducing the viral reservoir, which has historically resulted in low cure rates.
  • Microbiome Therapeutics: Leveraging a fully integrated platform, Assembly Biosciences has created a proprietary approach for identifying, isolating, and cultivating beneficial microbial strains. This platform, complemented by a patent-pending delivery technology, is designed to formulate oral live biotherapeutics that may address disorders associated with microbiome dysregulation.

Clinical Development and Research Focus

Assembly Biosciences operates at the forefront of antiviral drug development. Its clinical-stage programs are rigorously designed to assess safety, tolerability, and pharmacokinetics across multiple investigational candidates. The company’s robust pipeline is anchored by its commitment to advancing therapies that target the underlying mechanisms of viral infections, with research spanning from preclinical studies to early-stage clinical trials. The emphasis on oral delivery systems not only supports ease of administration but also reflects modern trends in patient-centric care.

Scientific Rationale & Differentiation

The research and development efforts are underscored by thorough mechanistic studies and innovative drug design strategies. By directly targeting key viral proteins and pathways, Assembly Biosciences aims to disrupt viral replication effectively. The incorporation of state-of-the-art strain selection methods in its microbiome program further highlights the company’s technical expertise. This combination of antiviral and microbiome-focused strategies provides a unique platform differentiating Assembly Biosciences from other entities in the competitive biotechnology landscape.

Market Position & Value Proposition

Positioned in a challenging segment of the biotechnology industry, Assembly Biosciences addresses significant unmet medical needs in the treatment of chronic viral infections. The company’s approach leverages long-standing expertise in virologic drug development and integrates rigorous clinical protocols with innovative oral delivery mechanisms. This has facilitated progress across multiple investigational therapies, which are being evaluated through well-designed clinical studies. The strategic emphasis on high-impact diseases such as HBV and conditions linked to microbiome imbalances establishes a clear value proposition to the public health sector.

Research Infrastructure and Strategic Collaborations

Assembly Biosciences benefits from an accomplished leadership team with extensive expertise in antiviral therapeutics and clinical research. Strategic collaborations with renowned partners further strengthen its research and development capabilities. This collaborative approach not only enhances the technical and clinical knowledge base but also provides a robust framework for addressing the safety and efficacy challenges associated with novel drug candidates.

Commitment to Innovation and Scientific Excellence

Underpinned by a deep commitment to scientific rigor and innovation, Assembly Biosciences continuously refines its therapeutic strategies by integrating advanced pharmacokinetic modeling, comprehensive preclinical assessments, and early-stage clinical data. The company’s methodical approach ensures that all therapeutic candidates are evaluated meticulously, thereby promoting a balanced view of potential benefits while maintaining high standards of safety and research integrity. This dedication forms the basis for sustained research excellence and positions Assembly Biosciences as a trusted informational resource in the biotechnology sector.

Rhea-AI Summary
Assembly Biosciences, Inc. (ASMB) has partnered with Gilead Sciences to develop treatments for herpesviruses, HBV, and HDV, with 4 candidates expected in clinical development by the end of 2024. The $100 million upfront payment and investment from Gilead extends cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
-
Rhea-AI Summary
ASMB: Assembly Biosciences Announces Dr. Anuj Gaggar as Chief Medical Officer, Bringing Infectious Disease Expertise to Antiviral Programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
Rhea-AI Summary
Gilead Sciences and Assembly Biosciences have entered into a 12-year partnership to develop antiviral therapies for herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). Assembly Bio will receive $100 million upfront payment, including an equity investment. Gilead may opt-in for exclusive rights to Assembly Bio's programs and could purchase up to 29.9% of Assembly Bio's voting stock. Assembly Bio may receive up to $330 million per program in potential milestones and royalties. Gilead's EPS is expected to be reduced by $0.05 - $0.07 in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
71.23%
Tags
partnership
Rhea-AI Summary
Assembly Biosciences to present preclinical and clinical data at AASLD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
-
Rhea-AI Summary
Assembly Biosciences selects development candidate ABI-6250 for IND-enabling studies targeting chronic hepatitis D virus (HDV) infection
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
none
-
Rhea-AI Summary
Assembly Biosciences to present new data on hepatitis B and hepatitis D pipeline programs at the 2023 International HBV Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
-
Rhea-AI Summary
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced preclinical data on ABI-5366, a long-acting herpes simplex virus (HSV) helicase inhibitor for high-recurrence genital herpes. The data showed potent antiviral activity against both HSV-1 and HSV-2, sustained plasma concentrations, and a favorable safety profile. The company plans to enter the clinic in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences

FAQ

What is the current stock price of Assembly Bioscie (ASMB)?

The current stock price of Assembly Bioscie (ASMB) is $9.39 as of April 1, 2025.

What is the market cap of Assembly Bioscie (ASMB)?

The market cap of Assembly Bioscie (ASMB) is approximately 68.8M.

What is the core focus of Assembly Biosciences?

Assembly Biosciences is a clinical-stage biotechnology company that develops innovative oral therapeutics for the treatment of chronic viral infections and disorders associated with microbiome dysregulation.

How does Assembly Biosciences generate revenue?

The company primarily pursues revenue through advancing its clinical-stage pipeline and establishing strategic collaborations, which may include licensing agreements and partnerships with industry leaders in antiviral and microbiome therapeutic research.

What therapeutic areas does the company target?

Assembly Biosciences focuses on addressing serious viral diseases such as hepatitis B and conditions related to microbiome imbalances through its dual-platform approach in antiviral and biotherapeutic research.

How do their HBV investigational therapies work?

Their HBV program is designed to disrupt multiple steps of the HBV lifecycle by using small-molecule agents that interfere with viral replication processes, potentially increasing cure rates compared to current treatments.

What sets their microbiome therapeutics apart?

The microbiome platform leverages an integrated technology that includes robust strain identification, precision isolation, and a patent-pending delivery system, ensuring targeted administration and improved therapeutic outcomes.

How is Assembly Biosciences positioned in the competitive landscape?

By combining rigorous clinical research with innovative oral delivery strategies, the company differentiates itself in a competitive market, addressing significant unmet needs in treatment of chronic viral infections and microbiome-associated disorders.

What role do strategic collaborations play in the company’s development efforts?

Collaborations with established industry partners bolster Assembly Biosciences' research capabilities, enhance its clinical development programs, and provide access to additional resources and expertise in antiviral drug development.

What are the key advantages of their oral therapeutic platforms?

Oral administration offers improved patient compliance and ease of use compared to traditional therapies, while the innovative designs of these platforms are supported by advanced pharmacokinetic studies and early clinical data demonstrating favorable safety profiles.
Assembly Bioscie

Nasdaq:ASMB

ASMB Rankings

ASMB Stock Data

68.75M
6.73M
12.15%
50.33%
0.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO